A Strategy to Identify de Novo Mutations in Common Disorders such as Autism and Schizophrenia

被引:7
|
作者
Julie, Gauthier [1 ,2 ]
Hamdan, Fadi F. [3 ,4 ]
Rouleau, Guy A. [5 ]
机构
[1] Univ Montreal, CHUM Res Ctr, Ctr Excellence Neur, Montreal, PQ H3C 3J7, Canada
[2] Univ Montreal, Dept Med, Montreal, PQ H3C 3J7, Canada
[3] Univ Montreal, CHU St Justine, Ctr Excellence Neur, Montreal, PQ H3C 3J7, Canada
[4] Univ Montreal, CHUM Notre Dame Res Ctr, Montreal, PQ H3C 3J7, Canada
[5] Univ Montreal, Dept Med, Montreal, PQ H3C 3J7, Canada
来源
关键词
Medicine; Issue; 52; de novo mutation; complex diseases; schizophrenia; autism; rare variations; DNA sequencing;
D O I
10.3791/2534
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
There are several lines of evidence supporting the role of de novo mutations as a mechanism for common disorders, such as autism and schizophrenia. First, the de novo mutation rate in humans is relatively high, so new mutations are generated at a high frequency in the population. However, de novo mutations have not been reported in most common diseases. Mutations in genes leading to severe diseases where there is a strong negative selection against the phenotype, such as lethality in embryonic stages or reduced reproductive fitness, will not be transmitted to multiple family members, and therefore will not be detected by linkage gene mapping or association studies. The observation of very high concordance in monozygotic twins and very low concordance in dizygotic twins also strongly supports the hypothesis that a significant fraction of cases may result from new mutations. Such is the case for diseases such as autism and schizophrenia. Second, despite reduced reproductive fitness(1) and extremely variable environmental factors, the incidence of some diseases is maintained worldwide at a relatively high and constant rate. This is the case for autism and schizophrenia, with an incidence of approximately 1% worldwide. Mutational load can be thought of as a balance between selection for or against a deleterious mutation and its production by de novo mutation. Lower rates of reproduction constitute a negative selection factor that should reduce the number of mutant alleles in the population, ultimately leading to decreased disease prevalence. These selective pressures tend to be of different intensity in different environments. Nonetheless, these severe mental disorders have been maintained at a constant relatively high prevalence in the worldwide population across a wide range of cultures and countries despite a strong negative selection against them(2). This is not what one would predict in diseases with reduced reproductive fitness, unless there was a high new mutation rate. Finally, the effects of paternal age: there is a significantly increased risk of the disease with increasing paternal age, which could result from the age related increase in paternal de novo mutations. This is the case for autism and schizophrenia(3). The male-to-female ratio of mutation rate is estimated at about 4-6:1, presumably due to a higher number of germ-cell divisions with age in males. Therefore, one would predict that de novo mutations would more frequently come from males, particularly older males(4). A high rate of new mutations may in part explain why genetic studies have so far failed to identify many genes predisposing to complexes diseases genes, such as autism and schizophrenia, and why diseases have been identified for a mere 3% of genes in the human genome. Identification for de novo mutations as a cause of a disease requires a targeted molecular approach, which includes studying parents and affected subjects. The process for determining if the genetic basis of a disease may result in part from de novo mutations and the molecular approach to establish this link will be illustrated, using autism and schizophrenia as examples.
引用
收藏
页数:5
相关论文
共 50 条
  • [41] Direct Measure of the De Novo Mutation Rate in Autism and Schizophrenia Cohorts
    Awadalla, Philip
    Gauthier, Julie
    Myers, Rachel A.
    Casals, Ferran
    Hamdan, Fadi F.
    Griffing, Alexander R.
    Cote, Melanie
    Henrion, Edouard
    Spiegelman, Dan
    Tarabeux, Julien
    Piton, Amelie
    Yang, Yan
    Boyko, Adam
    Bustamante, Carlos
    Xiong, Lan
    Rapoport, Judith L.
    Addington, Aniene M.
    DeLisi, J. Lynn E.
    Krebs, Marie-Odile
    Joober, Ridha
    Millet, Bruno
    Fombonne, Eric
    Mottron, Laurent
    Zilversmit, Martine
    Keebler, Jon
    Daoud, Hussein
    Marineau, Claude
    Roy-Gagnon, Marie-Helene
    Dube, Marie-Pierre
    Eyre-Walker, Adam
    Drapeau, Pierre
    Stone, Eric A.
    Lafreniere, Ronald G.
    Rouleau, Guy A.
    AMERICAN JOURNAL OF HUMAN GENETICS, 2010, 87 (03) : 316 - 324
  • [42] Exome sequencing to identify de novo mutations in sporadic ALS trios
    Alessandra Chesi
    Brett T Staahl
    Ana Jovičić
    Julien Couthouis
    Maria Fasolino
    Alya R Raphael
    Tomohiro Yamazaki
    Laura Elias
    Meraida Polak
    Crystal Kelly
    Kelly L Williams
    Jennifer A Fifita
    Nicholas J Maragakis
    Garth A Nicholson
    Oliver D King
    Robin Reed
    Gerald R Crabtree
    Ian P Blair
    Jonathan D Glass
    Aaron D Gitler
    Nature Neuroscience, 2013, 16 : 851 - 855
  • [43] Exome sequencing to identify de novo mutations in sporadic ALS trios
    Chesi, Alessandra
    Staahl, Brett T.
    Jovicic, Ana
    Couthouis, Julien
    Fasolino, Maria
    Raphael, Alya R.
    Yamazaki, Tomohiro
    Elias, Laura
    Polak, Meraida
    Kelly, Crystal
    Williams, Kelly L.
    Fifita, Jennifer A.
    Maragakis, Nicholas J.
    Nicholson, Garth A.
    King, Oliver D.
    Reed, Robin
    Crabtree, Gerald R.
    Blair, Ian P.
    Glass, Jonathan D.
    Gitler, Aaron D.
    NATURE NEUROSCIENCE, 2013, 16 (07) : 851 - U98
  • [44] WHOLE GENOME SEQUENCING TO IDENTIFY DE NOVO MUTATIONS IN BIPOLAR DISORDER
    Goes, Fernando
    Pirooznia, Mehdi
    Tehan, Martin
    Wolyniec, Paula
    McGrath, John
    Nested, Gerald
    Apulver, Ann
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2017, 27 : S384 - S384
  • [45] De novo POGZ mutations are associated with neurodevelopmental disorders and microcephaly
    Ye, Yizhou
    Cho, Megan T.
    Retterer, Kyle
    Alexander, Nora
    Ben-Omran, Tawfeg
    Al-Mureikhi, Mariam
    Cristian, Ingrid
    Wheeler, Patricia G.
    Crain, Carrie
    Zand, Dina
    Weinstein, Veronique
    Vernon, Hilary J.
    McClellan, Rebecca
    Krishnamurthy, Vidya
    Vitazka, Patrik
    Milian, Francisca
    Chung, Wendy K.
    COLD SPRING HARBOR MOLECULAR CASE STUDIES, 2015, 1 (01):
  • [46] De novo mutations in regulatory elements cause neurodevelopmental disorders
    Short, P.
    McRae, J.
    Gallone, G.
    Gerety, S.
    Wright, C.
    Firth, H.
    FitzPatrick, D.
    Barrett, J.
    Hurles, M.
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2018, 26 : 41 - 42
  • [47] The Role of De Novo Noncoding Regulatory Mutations in Neurodevelopmental Disorders
    Turner, Tychele N.
    Eichler, Evan E.
    TRENDS IN NEUROSCIENCES, 2019, 42 (02) : 115 - 127
  • [48] THE EMERGING LANDSCAPE OF SCHIZOPHRENIA RISK CONFERRED BY DE NOVO CODING MUTATIONS
    Howrtgan, Daniel
    Neale, Benjamin
    Samocha, Kaitlin
    Moran, Jennifer
    Chambert, Kimberly
    Rose, Samuel
    Fromer, Menachem
    Chandler, Sharon
    Laird, Nan
    Hwu, Hai-Gwo
    Chen, Wei J.
    Faraone, Stephen
    Glatt, Stephen
    Tsuang, Ming
    McCarroll, Steven
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2017, 27 : S346 - S347
  • [49] DAMAGING MISSENSE DE NOVO CODING MUTATIONS CONTRIBUTE TO SCHIZOPHRENIA RISK
    Howrigan, Daniel
    Samocha, Kaitlin
    Kosmicki, Jack
    Moran, Jennifer
    Chambert, Kimberly
    Fromer, Menachem
    Chandler, Sharon
    Laird, Nan
    Hwu, Hai-Gwo
    Chen, Wei J.
    Faraone, Stephen
    Glatt, Stephen
    Tsuang, Ming
    McCarroll, Steven
    Neale, Benjamin
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2017, 27 : S427 - S428
  • [50] Strong association of de novo copy number mutations with sporadic schizophrenia
    Bin Xu
    J Louw Roos
    Shawn Levy
    E J van Rensburg
    Joseph A Gogos
    Maria Karayiorgou
    Nature Genetics, 2008, 40 : 880 - 885